Publications (67) Ana Alfonso Piérola publications

filter_list

2026

  1. Haemostatic changes during CART cell therapy and risk of complications

    Cancer Immunology, Immunotherapy, Vol. 75, Núm. 4

  2. Integrated Single-Cell and Spatial Multi-Omics of Clonal Precursors and Immune Niches in Germinal Center Lymphomas

    Cancers, Vol. 18, Núm. 7

  3. Quizartinib in Combination With FLAG-IDA for Relapsed or Refractory Acute Myeloid Leukemia (FLAG-QUIDA): A PETHEMA Phase I-II Trial

    American Journal of Hematology, Vol. 101, Núm. 9, pp. 2258-2268

  4. Reassessing adverse prognosis of acute myeloid leukemia harboring BCR::ABL1 in the era of tyrosine kinase inhibitors: A real-world analysis from the PETHEMA registry

    Cancer, Vol. 132, Núm. 8

  5. Single-cell multiomics reveals regulatory mechanisms of CAR T-cell persistence and dysfunction in multiple myeloma

    Blood Neoplasia, Vol. 3, Núm. 2

2025

  1. A phase 1, first-in-human, dose-escalation study of JNJ-74856665 (dihydroorotate dehydrogenase inhibitor) alone or in combination in patients with AML or MDS

    British Journal of Haematology, Vol. 207, Núm. 2, pp. 624-630

  2. Enasidenib as treatment for AML with IDH2 mutation: multicenter real-life study of the early-access program in Spain

    Annals of Hematology

  3. From Sanger to Oxford Nanopore MinION Technology: The Impact of Third-Generation Sequencing on Genetic Hematological Diagnosis

    Cancers, Vol. 17, Núm. 11

  4. Generation and GMP scale-up of human CAR-T cells using non-viral Sleeping Beauty transposons for B cell malignances

    Molecular Therapy Methods and Clinical Development, Vol. 33, Núm. 1

  5. Hematopoietic Stem Cell Hierarchies as Novel Biomarkers of Drug Response in Myelodysplastic Syndromes and Acute Myeloid Leukemia

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 31, Núm. 17, pp. 3618-3627

  6. Long-term benefits of autologous stem cell transplantation versus intensive chemotherapy consolidation for acute myeloid leukemia patients: A propensity score matching analysis from the PETHEMA AML registry

    Leukemia, Vol. 39, Núm. 11, pp. 2686-2696

  7. Phase 1 first-in-human dose-expansion study of the oral SF3B1 modulator H3B‑8800 in lower-risk myelodysplastic syndrome

    Leukemia Research, Vol. 156

  8. Treatment patterns and outcomes in secondary acute myeloid leukemia arising after hypomethylating agents: PETHEMA registry study

    Cancer, Vol. 131, Núm. 1

  9. Unraveling clonal hematopoiesis of indeterminate potential (CHIP) in cancer: Prevalence, clonal dynamics, and prognostic significance.

    Journal of Clinical Oncology, Vol. 43, pp. e22524-e22524

2024

  1. Epigenetic-based differentiation therapy for Acute Myeloid Leukemia

    Nature Communications, Vol. 15, Núm. 1

  2. First-in-human study of JNJ-67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome

    Clinical and Translational Science, Vol. 17, Núm. 3

  3. Molecular mechanisms promoting long-term cytopenia after BCMA CAR-T therapy in multiple myeloma

    Blood Advances, Vol. 8, Núm. 21, pp. 5479-5492

  4. Myelodysplastic neoplasms

    Medicina Clinica, Vol. 162, Núm. 2, pp. 77-82

  5. Single-cell transcriptional profile of CD34+ hematopoietic progenitor cells from del(5q) myelodysplastic syndromes and impact of lenalidomide

    Nature Communications, Vol. 15, Núm. 1

  6. Síndromes mielodisplásicos. Neoplasias mielodisplásicas/ mieloproliferativas

    Pregrado de Hematología (Asociación Española de Hematologia y Hemoterapia), pp. 545-566